SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials
| العنوان: | SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials |
|---|---|
| المؤلفون: | Marie-Philippe Saltiel, Robert Puckrin, Pauline Reynier, Laurent Azoulay, Kristian B. Filion, Oriana Hoi Yun Yu |
| المصدر: | Acta Diabetologica. 55:503-514 |
| بيانات النشر: | Springer Science and Business Media LLC, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, Type 2 diabetes, Infections, Placebo, law.invention, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Endocrinology, Glucosides, Sodium-Glucose Transporter 2, Randomized controlled trial, Risk Factors, law, Internal medicine, Internal Medicine, Humans, Hypoglycemic Agents, Medicine, 030212 general & internal medicine, Benzhydryl Compounds, Dapagliflozin, Adverse effect, Sodium-Glucose Transporter 2 Inhibitors, Randomized Controlled Trials as Topic, Respiratory tract infections, business.industry, General Medicine, medicine.disease, Diabetes Mellitus, Type 2, chemistry, Relative risk, Meta-analysis, business |
| الوصف: | There is concern about the infection-related safety profile of sodium–glucose co-transporter 2 (SGLT-2) inhibitors. We aimed to determine the effect of SGLT-2 inhibitors on genitourinary and other infections via systematic review and meta-analysis of randomized controlled trials (RCTs). We conducted a systematic search of Medline, EMBASE, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov to identify double-blinded RCTs enrolling ≥ 50 patients with type 2 diabetes which compared an SGLT-2 inhibitor to placebo or active comparator. Two independent reviewers extracted data and appraised study quality. Data were pooled using random-effects models. Eighty-six RCTs enrolling 50,880 patients were included. SGLT-2 inhibitors increased the risk of genital infections compared to placebo (relative risk [RR] 3.37, 95% CI 2.89–3.93, I2 0%) and active comparator (RR 3.89, 95% CI 3.14–4.82, I2 0.3%). The risk of urinary tract infection (UTI) was not increased with SGLT-2 inhibitors compared to placebo (RR 1.03, 95% CI 0.96–1.11, I2 0%) or active comparator (RR 1.08, 95% CI 0.93–1.25, I2 22%). In drug-specific analyses, only dapagliflozin 10 mg daily was associated with a significantly increased risk of UTI compared to placebo (RR 1.33, 95% CI 1.10–1.61, I2 0%). SGLT-2 inhibitors were associated with a reduced risk of gastroenteritis (RR 0.38, 95% CI 0.20–0.72, I2 0%) but did not affect the risk of respiratory tract infections. SGLT-2 inhibitors are associated with an increased risk of genital tract infections. Although there is no association overall between SGLT-2 inhibitors and UTI, higher doses of dapagliflozin are associated with an increased risk. |
| تدمد: | 1432-5233 0940-5429 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd95eb05f85172bdb9075eabbc46ae3cTest https://doi.org/10.1007/s00592-018-1116-0Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....cd95eb05f85172bdb9075eabbc46ae3c |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14325233 09405429 |
|---|